BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 9894769)

  • 1. Timing of breast cancer surgery within the menstrual cycle: tumor proliferative activity, receptor status and short-term clinical outcome.
    Mangia A; De Lena M; Barletta A; Marzullo F; Attolico M; Stea B; Petroni S; Labriola A; Cellamare G; Digiesi G; Altieri R; Schittulli F; Paradiso A
    J Exp Clin Cancer Res; 1998 Sep; 17(3):317-23. PubMed ID: 9894769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause.
    Pujol P; Daures JP; Thezenas S; Guilleux F; Rouanet P; Grenier J
    Cancer; 1998 Aug; 83(4):698-705. PubMed ID: 9708933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-proliferative activity, progesterone receptor status, estrogen receptor level, and clinical outcome of estrogen receptor-positive advanced breast cancer.
    Paradiso A; Tommasi S; Mangia A; Lorusso V; Simone G; De Lena M
    Cancer Res; 1990 May; 50(10):2958-62. PubMed ID: 2334898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective prognostic study of the hormonal milieu at the time of surgery in premenopausal breast carcinoma.
    Pujol P; Daures JP; Brouillet JP; Chang S; Rouanet P; Bringer J; Grenier J; Maudelonde T
    Cancer; 2001 May; 91(10):1854-61. PubMed ID: 11346866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Relationship of estrogen and progesterone receptors to the menstrual cycle and menopausal status at the time of breast surgery].
    Karbowski B; Jackisch C; Deppe B; Schneider HP
    Zentralbl Gynakol; 1999; 121(8):367-74. PubMed ID: 10486879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression of steroid receptors and DNA synthesis in male breast cancer].
    Petroni S; Mangia A; D'Amico C; Simone G
    Pathologica; 2003 Feb; 95(1):31-6. PubMed ID: 12735283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
    Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
    J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Menstrual cycle and hormone receptor status in breast cancer patients.
    Atalay C; Kanliöz M; Altinok M
    Neoplasma; 2002; 49(4):278. PubMed ID: 12382029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
    Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
    J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast carcinoma cell kinetics, morphology, stage, and host characteristics. A thymidine labeling study.
    Meyer JS; Prey MU; Babcock DS; McDivitt RW
    Lab Invest; 1986 Jan; 54(1):41-51. PubMed ID: 3941541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Timing of breast cancer surgery during the luteal menstrual phase may improve prognosis.
    Lemon HM; Rodriguez-Sierra JF
    Nebr Med J; 1996 Mar; 81(3):73-8. PubMed ID: 8907825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Timing of breast cancer surgery during the luteal menstrual phase may improve prognosis.
    Lemon HM; Rodriguez-Sierra JF
    Nebr Med J; 1996 Apr; 81(4):110-5. PubMed ID: 8628449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with prognosis in human breast cancer. IV. Progesterone receptors and clinical factors.
    Macías A; Pascual MR; Pérez R; Lage A
    Neoplasma; 1983; 30(5):593-601. PubMed ID: 6656963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
    Dowsett M; Allred C; Knox J; Quinn E; Salter J; Wale C; Cuzick J; Houghton J; Williams N; Mallon E; Bishop H; Ellis I; Larsimont D; Sasano H; Carder P; Cussac AL; Knox F; Speirs V; Forbes J; Buzdar A
    J Clin Oncol; 2008 Mar; 26(7):1059-65. PubMed ID: 18227529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
    Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Pater JL;
    J Clin Oncol; 2007 May; 25(15):2006-11. PubMed ID: 17452676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variations in steroid hormone receptor content throughout age and menopausal periods, and menstrual cycle in breast cancer patients.
    Nikolić-Vukosavljević D; Vasiljević N; Branković-Magić M; Polić D
    Neoplasma; 1996; 43(3):163-9. PubMed ID: 8841503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.